Lesotho Among First Nations to Receive Groundbreaking HIV Prevention Drug Lenacapavir

Lesotho has emerged as one of the first nine countries in the world selected to receive lenacapavir (LEN), a revolutionary long-acting injectable for HIV pre-exposure prophylaxis (PrEP). This milestone development was officially announced by the Global Fund following a landmark agreement with Gilead Sciences, which will provide the drug at no profit to low- and middle-income countries.

Lenacapavir is poised to transform the landscape of HIV prevention, particularly in regions like Lesotho where the burden of HIV remains high. Unlike traditional oral PrEP methods that require daily adherence, LEN offers a much simpler alternative—just two injections per year. The injectable not only enhances convenience but also ensures a more discreet method of protection for those at high risk of infection.

According to data from recent clinical trials, LEN demonstrated nearly 100% effectiveness in preventing HIV, with no infections reported among women in high-incidence areas who received the drug. Experts say this could significantly reduce new infections, especially among young women and other vulnerable groups.

The Global Fund is expected to dispatch its first shipments of LEN to Lesotho before the end of 2025. A national rollout is projected for early 2026, pending final regulatory approval. In anticipation, the Ministry of Health in Lesotho has begun working on regulatory clearance, supply chain logistics, and budgetary frameworks to ensure a smooth launch.

International support has also been mobilized to bolster Lesotho’s readiness. Development partners including the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) have pledged technical assistance and capacity-building support.

The introduction of LEN marks a bold step forward in HIV prevention, offering hope for thousands in Lesotho and setting a new standard for long-acting, user-friendly PrEP solutions worldwide. As the country prepares to roll out this innovative treatment, health officials and global partners remain optimistic that LEN will accelerate progress toward ending new HIV infections by 2030.